113 related articles for article (PubMed ID: 32156786)
1. Decitabine Response in Breast Cancer Requires Efficient Drug Processing and Is Not Limited by Multidrug Resistance.
Dahn ML; Cruickshank BM; Jackson AJ; Dean C; Holloway RW; Hall SR; Coyle KM; Maillet H; Waisman DM; Goralski KB; Giacomantonio CA; Weaver ICG; Marcato P
Mol Cancer Ther; 2020 May; 19(5):1110-1122. PubMed ID: 32156786
[TBL] [Abstract][Full Text] [Related]
2. S-adenosylmethionine in combination with decitabine shows enhanced anti-cancer effects in repressing breast cancer growth and metastasis.
Mahmood N; Arakelian A; Cheishvili D; Szyf M; Rabbani SA
J Cell Mol Med; 2020 Sep; 24(18):10322-10337. PubMed ID: 32720467
[TBL] [Abstract][Full Text] [Related]
3. DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine.
Yu J; Qin B; Moyer AM; Nowsheen S; Liu T; Qin S; Zhuang Y; Liu D; Lu SW; Kalari KR; Visscher DW; Copland JA; McLaughlin SA; Moreno-Aspitia A; Northfelt DW; Gray RJ; Lou Z; Suman VJ; Weinshilboum R; Boughey JC; Goetz MP; Wang L
J Clin Invest; 2018 Jun; 128(6):2376-2388. PubMed ID: 29708513
[TBL] [Abstract][Full Text] [Related]
4. Decitabine potentiates efficacy of doxorubicin in a preclinical trastuzumab-resistant HER2-positive breast cancer models.
Buocikova V; Longhin EM; Pilalis E; Mastrokalou C; Miklikova S; Cihova M; Poturnayova A; Mackova K; Babelova A; Trnkova L; El Yamani N; Zheng C; Rios-Mondragon I; Labudova M; Csaderova L; Kuracinova KM; Makovicky P; Kucerova L; Matuskova M; Cimpan MR; Dusinska M; Babal P; Chatziioannou A; Gabelova A; Rundén-Pran E; Smolkova B
Biomed Pharmacother; 2022 Mar; 147():112662. PubMed ID: 35091237
[TBL] [Abstract][Full Text] [Related]
5. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB
Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068
[TBL] [Abstract][Full Text] [Related]
6. Combination of azacytidine and curcumin is a potential alternative in decitabine-resistant colorectal cancer cells with attenuated deoxycytidine kinase.
Hosokawa M; Seiki R; Iwakawa S; Ogawara KI
Biochem Biophys Res Commun; 2021 Nov; 578():157-162. PubMed ID: 34571370
[TBL] [Abstract][Full Text] [Related]
7. Activation of Estrogen Receptor Alpha by Decitabine Inhibits Osteosarcoma Growth and Metastasis.
Lillo Osuna MA; Garcia-Lopez J; El Ayachi I; Fatima I; Khalid AB; Kumpati J; Slayden AV; Seagroves TN; Miranda-Carboni GA; Krum SA
Cancer Res; 2019 Mar; 79(6):1054-1068. PubMed ID: 30593524
[TBL] [Abstract][Full Text] [Related]
8. Hypermethylation of lncRNA MEG3 impairs chemosensitivity of breast cancer cells.
Li H; Wang P; Liu J; Liu W; Wu X; Ding J; Kang J; Li J; Lu J; Pan G
J Clin Lab Anal; 2020 Sep; 34(9):e23369. PubMed ID: 32618397
[TBL] [Abstract][Full Text] [Related]
9. Decitabine enhances tumor recognition by T cells through upregulating the MAGE-A3 expression in esophageal carcinoma.
Shi X; Chen X; Fang B; Ping Y; Qin G; Yue D; Li F; Yang S; Zhang Y
Biomed Pharmacother; 2019 Apr; 112():108632. PubMed ID: 30797153
[TBL] [Abstract][Full Text] [Related]
10. Integrated epigenetics of human breast cancer: synoptic investigation of targeted genes, microRNAs and proteins upon demethylation treatment.
Radpour R; Barekati Z; Kohler C; Schumacher MM; Grussenmeyer T; Jenoe P; Hartmann N; Moes S; Letzkus M; Bitzer J; Lefkovits I; Staedtler F; Zhong XY
PLoS One; 2011; 6(11):e27355. PubMed ID: 22076154
[TBL] [Abstract][Full Text] [Related]
11. Altered DNA methylation is associated with docetaxel resistance in human breast cancer cells.
Kastl L; Brown I; Schofield AC
Int J Oncol; 2010 May; 36(5):1235-41. PubMed ID: 20372798
[TBL] [Abstract][Full Text] [Related]
12. The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models.
Gómez-Miragaya J; Morán S; Calleja-Cervantes ME; Collado-Sole A; Paré L; Gómez A; Serra V; Dobrolecki LE; Lewis MT; Diaz-Lagares A; Eroles P; Prat A; Esteller M; González-Suárez E
Mol Cancer Res; 2019 Oct; 17(10):2063-2076. PubMed ID: 31320385
[TBL] [Abstract][Full Text] [Related]
13. miR-155 increases stemness and decitabine resistance in triple-negative breast cancer cells by inhibiting TSPAN5.
Yang LW; Wu XJ; Liang Y; Ye GQ; Che YC; Wu XZ; Zhu XJ; Fan HL; Fan XP; Xu JF
Mol Carcinog; 2020 Apr; 59(4):447-461. PubMed ID: 32096299
[TBL] [Abstract][Full Text] [Related]
14. Decitabine rescues cisplatin resistance in head and neck squamous cell carcinoma.
Viet CT; Dang D; Achdjian S; Ye Y; Katz SG; Schmidt BL
PLoS One; 2014; 9(11):e112880. PubMed ID: 25391133
[TBL] [Abstract][Full Text] [Related]
15. Deoxycytidine kinase is overexpressed in poor outcome breast cancer and determines responsiveness to nucleoside analogs.
Geutjes EJ; Tian S; Roepman P; Bernards R
Breast Cancer Res Treat; 2012 Feb; 131(3):809-18. PubMed ID: 21465168
[TBL] [Abstract][Full Text] [Related]
16. Genomic screening for genes upregulated by demethylation revealed novel targets of epigenetic silencing in breast cancer.
Fujikane T; Nishikawa N; Toyota M; Suzuki H; Nojima M; Maruyama R; Ashida M; Ohe-Toyota M; Kai M; Nishidate T; Sasaki Y; Ohmura T; Hirata K; Tokino T
Breast Cancer Res Treat; 2010 Aug; 122(3):699-710. PubMed ID: 19859801
[TBL] [Abstract][Full Text] [Related]
17. Methylation decreases the Bin1 tumor suppressor in ESCC and restoration by decitabine inhibits the epithelial mesenchymal transition.
Wang X; Wang J; Jia Y; Wang Y; Han X; Duan Y; Lv W; Ma M; Liu L
Oncotarget; 2017 Mar; 8(12):19661-19673. PubMed ID: 28152502
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells.
Li SY; Sun R; Wang HX; Shen S; Liu Y; Du XJ; Zhu YH; Jun W
J Control Release; 2015 May; 205():7-14. PubMed ID: 25445694
[TBL] [Abstract][Full Text] [Related]
19. Decitabine-Mediated Epigenetic Reprograming Enhances Anti-leukemia Efficacy of CD123-Targeted Chimeric Antigen Receptor T-Cells.
You L; Han Q; Zhu L; Zhu Y; Bao C; Yang C; Lei W; Qian W
Front Immunol; 2020; 11():1787. PubMed ID: 32973749
[TBL] [Abstract][Full Text] [Related]
20. Methylation-dependent silencing of the reduced folate carrier gene in inherently methotrexate-resistant human breast cancer cells.
Worm J; Kirkin AF; Dzhandzhugazyan KN; Guldberg P
J Biol Chem; 2001 Oct; 276(43):39990-40000. PubMed ID: 11509559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
